Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.

[1]  M. Zelefsky,et al.  Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. , 2017, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[2]  A. Katz.  Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis , 2017, Cureus.

[3]  J. Mechalakos,et al.  Clinical workflow for MR-only simulation and planning in prostate , 2017, Radiation oncology.

[4]  N. Van As,et al.  Stereotactic body radiotherapy for prostate cancer. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  Constantine Mantz,et al.  A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum Follow-Up , 2014, Front. Oncol..

[6]  M. Parmar,et al.  Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. , 2014, The Lancet. Oncology.

[7]  Jason Wang,et al.  Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Liying Zhang,et al.  Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  James D Brooks,et al.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[10]  P. Maingon,et al.  70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. , 2011, International journal of radiation oncology, biology, physics.

[11]  Kyounghwa Bae,et al.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Lebesque,et al.  Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[13]  Victor E Reuter,et al.  Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. , 2008, The Journal of urology.

[14]  Yoshiya Yamada,et al.  Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. , 2006, The Journal of urology.

[15]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.